Takeda Pharmaceuticals Faces $885 Million Verdict Over Anticompetitive Drug Patent Agreement
In a significant development, a federal jury in Massachusetts has delivered an $885 million verdict against Takeda Pharmaceuticals Co., scrutinizing the limits of pay-for-delay agreements in the pharmaceutical industry. The verdict found Takeda guilty of engaging in anticompetitive behavior by entering a patent settlement with a generic manufacturer, which delayed the entry of a generic…